---
title: "Beijing Aosaikang Pharmaceutical Co.,Ltd. (002755.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002755.SZ.md"
symbol: "002755.SZ"
name: "Beijing Aosaikang Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:35:35.413Z"
locales:
  - [en](https://longbridge.com/en/quote/002755.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002755.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002755.SZ.md)
---

# Beijing Aosaikang Pharmaceutical Co.,Ltd. (002755.SZ)

## Company Overview

Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, including the treatment of non-small cell lung cancer, colorectal cancer, and breast cancer, encompassing targeted therapy, chemotherapy, endocrine therapy, and adjuvant medications. In addition, the company provides anti-infective products comprising a product defense line against bacterial and invasive fungal infections; and the chronic disease field focusing on chronic diseases requiring long-term management consisting of diabetes, osteoarthritis, thrombocytopenia, and iron overload.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.ask-pharm.com](https://www.ask-pharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 87 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -4.65% |  |
| Net Profit YoY | 45.16% |  |
| P/B Ratio | 4.54 |  |
| Dividend Ratio | 0.74% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14997855864.69 |  |
| Revenue | 1755368239.40 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.26% | B |
| Profit Margin | 15.20% | A |
| Gross Margin | 84.10% | A |
| Revenue YoY | -4.65% | D |
| Net Profit YoY | 45.16% | B |
| Total Assets YoY | 6.45% | B |
| Net Assets YoY | 4.78% | C |
| Cash Flow Margin | 245.05% | A |
| OCF YoY | -4.65% | D |
| Turnover | 0.40 | C |
| Gearing Ratio | 25.28% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beijing Aosaikang Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-4.65%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "45.16%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.74%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14997855864.69",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1755368239.40",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.26%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "15.20%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "84.10%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-4.65%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "45.16%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.45%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.78%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "245.05%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-4.65%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.40",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "25.28%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 59.59 | 114/215 | 87.41 | 67.03 | 57.77 |
| PB | 4.81 | 184/215 | 6.20 | 4.99 | 4.63 |
| PS (TTM) | 9.06 | 177/215 | 10.44 | 8.83 | 8.10 |
| Dividend Yield | 0.70% | 115/215 | 0.75% | 0.70% | 0.56% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-04T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.10 |
| Highest Target | 23.00 |
| Lowest Target | 23.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002755.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002755.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002755.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002755.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**